Spruce Street Capital »

Alkermes shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $29M 544k 52.40

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Alkermes

BlackRock
Baker Bros. Advisors
Vanguard Portfolio Management
State Street Corporation
Vanguard Capital Management
Renaissance Technologies
T. Rowe Price Associates
Commodore Capital
Dimensional Fund Advisors
Geode Capital Management
American Century Companies
Deep Track Capital
Wellington Management Company
PRIMECAP Management Company
Nuveen

View all funds holding Alkermes